

ATTORNEY DOCKET NO. 21105.0011U2  
PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of	)	
	)	
ROWE	)	Art Unit: Unassigned
	)	
Application No. 10/567,938	)	Examiner: Unassigned
International Application No. PCT/US2004/030530	)	
	)	Confirmation No. Unassigned
Filing Date: February 9, 2006	)	
International Filing Date: September 20, 2004	)	
	)	
For: REGULATION OF TISSUE	)	
MINERALIZATION AND PHOSPHATE	)	
METABOLISM BY ASARM PEPTIDES	)	

**INFORMATION DISCLOSURE STATEMENT**

Mail Stop PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

NEEDLE & ROSENBERG, P.C.  
Customer No. 23859

June 30, 2006

Sir:

Pursuant to the requirements of 37 C.F.R. § 1.56, submitted herewith on the accompanying Information Disclosure Statement List is a listing of documents known to Applicants and/or their attorneys. In accordance with 37 C.F.R. § 1.98(a)(2), copies of any cited U.S. patent or U.S. patent application publication documents are not enclosed. Copies of any cited foreign patent document and/or any non-patent publication are enclosed.

This Information Disclosure Statement is believed to be filed in a timely manner pursuant to 37 C.F.R. § 1.97(b)(3), in that a first Office Action on the merits of the present patent application has not yet been mailed to Applicants.


Consideration of the cited documents and making the same of record in the prosecution of the above-referenced application are respectfully requested.

**ATTORNEY DOCKET NO. 21105.0011U2**  
**Application No. 10/567,938**

No fee is believed due; however, the Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 14-0629.

Respectfully submitted,

NEEDLE & ROSENBERG, P.C.




Christopher L. Curfman, JD, PhD  
Registration No. 52,787

NEEDLE & ROSENBERG, P.C.  
Customer Number 23859  
(678) 420-9300  
(678) 420-9301 (fax)

**CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8**

I hereby certify that this correspondence, including any items indicated as attached or included, is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below.

  
Christopher L. Curfman

June 30, 2006  
Date

<b>INFORMATION DISCLOSURE STATEMENT LIST</b>  (Use as many sheets as necessary)	Complete if Known	
	Application No.	10/567,938
	Filing Date	February 9, 2006
	First Named Inventor	Rowe, Peter S.N.
	Group Art Unit	Unassigned
Examiner Name	Unassigned	

U.S. PATENT DOCUMENTS							
Examiner's Initials	Cite No.	Document No.	Date	Name	Class	Subclass	Filing Date (if appropriate)
	A1	2004/0053389	03/18/2004	Rowe	435	196	
	A2	2003/064498	04/03/2003	Rowe	435	196	

FOREIGN PATENT DOCUMENTS					
Examiner's Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code	Date	Name	Translation Yes/No
	A3	EP 1293568 A1	06/20/2001	Kurokawa et al.	

NON-PATENT DOCUMENTS		
	A4	Agarwal and Knochel, "Hypophosphatemia and Hyperphosphatemia," In: Brenner & Rector's <i>The Kidney</i> , 6 <sup>th</sup> ed., (2000), WB Saunders Co.
	A5	Aisa et al., "Cathepsin B in osteoblasts," <i>Biochim Biophys Acta</i> , 1621:149-59, (2003).
	A6	Aisa et al., "Cathepsin B activity in normal human osteoblast-like cells and human osteoblastic osteosarcoma cells (MG-63): regulation by interleukin-1 beta and parathyroid hormone," <i>Biochim Biophys Acta</i> , 1290:29-36, (1996).
	A7	Argiro et al., "Mepe, the gene encoding a tumor-secreted protein in oncogenic hypophosphatemic osteomalacia, is expressed in bone," <i>Genomics</i> , 74:342-51, (2001).
	A8	Bai, X. et al., "Partial Rescue of the Hyp Phenotype by Osteoblast-Targeted PHEX (Phosphate-Regulating Gene with Homologies to Endopeptidases on the X Chromosome) Expression," <i>Mol Endocrinol</i> , 16:2913-25, (2002).
	A9	Bennick et al., "The location and nature of calcium-binding sites in salivary acidic praline-rich phosphoproteins," <i>J Biol Chem</i> , 256:4741-46, (1981).
	A10	Bhargava et al., "Ultrastructural analysis of bone nodules formed <i>in vivo</i> by isolated fetal rat calvaria cells," <i>Bone</i> , 9:155-63, (1988).
	A11	Boileau et al., "Characterization of PHEX endopeptidase catalytic activity: Identification of parathyroid-hormone-related peptide 107-139 as a substrate and osteocalcin, PPI and phosphate as inhibitors," <i>Biochem J</i> , 355(Pt 3):707-13, (2001).
	A12	Bonjour et al., "Action of 1,25-dihydroxyvitamin D3 and a diphosphonate on calcium metabolism in rats," <i>Am J Physiol</i> , 229(2):402-8, (1975).
	A13	Bresler et al., "Serum MEPE-ARARM peptides are elevated in x-linked rickets (HYP) and cause phosphaturia and defective mineralization," <i>J Endocrinol</i> , 183:R1-R9, (2004).
	A14	Cai, Q. et al., "Brief report: inhibition of renal phosphate transport by a tumor product in a patient with oncogenic osteomalacia," <i>N. Engl. J. Med.</i> , 330:1645-49, (1994).
	A15	Campos et al., "Human recombinant endopeptidase PHEX has a strict S1 specificity for acidic residues and cleaves peptides derived from fibroblast growth factor-23 and matrix extracellular phosphoglycoprotein," <i>Biochem J</i> , 373(Pt 1):271-9, (2003).
	A16	Carpenter et al., "Osteocalcin production in primary osteoblast cultures derived from normal and Hyp mice," <i>Endocrinology</i> , 139:35-43, (1998).
	A17	Chen et al., "Differential roles for bone morphogenetic protein (BMP) receptor type IB and IA in differentiation and specification of mesenchymal precursor cells to osteoblast and adipocyte lineages," <i>J Cell Biol</i> , 142:295-305, (1998).

Examiner Signature:	Date Considered:
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

<b>INFORMATION DISCLOSURE STATEMENT LIST</b>  (Use as many sheets as necessary)		Complete if Known	
		Application No.	10/567,938
		Filing Date	February 9, 2006
		First Named Inventor	Rowe, Peter S.N.
		Group Art Unit	Unassigned
Examiner Name	Unassigned		
	A18	De Beur, "Tumors associated with oncogenic osteomalacia express genes important in bone and mineral metabolism," <i>J Bone Miner Res</i> , 17:1102-10, (2002).	
	A19	Donath and Breuner, "A method for the study of undecalcified bones and teeth with attached soft tissues. The Sage-Schliff (sawing and grinding) technique," <i>J Oral Pathol</i> , 11(4):318-26, (1982).	
	A20	Drezner, "Tumor-induced osteomalacia," <i>Rev Endocr Metab Disord</i> , 2:175-86, (2001).	
	A21	Dubois et al., "Role of abnormal neutral endopeptidase-like activities in Hyp mouse bone cells in renal phosphate transport," <i>Am J Physiol Cell Physiol</i> , 283:C1414-21, (2002).	
	A22	Ecarot et al., "Defective bone formation by Hyp mouse bone cells transplanted into normal mice: evidence in favor of an intrinsic osteoblast defect," <i>J Bone Miner Res</i> , 7:215-20, (1992).	
	A23	Ecarot et al., "Effect of 1,25-dihydroxyvitamin D3 treatment on bone formation by transplanted cells from normal and X-linked hypophosphatemic mice," <i>J Bone Miner Res</i> , 10:424-31, (1995).	
	A24	Ecarot et al., "Effect of dietary phosphate deprivation and supplementation of recipient mice on bone formation by transplanted cells from normal and X-linked hypophosphatemic mice," <i>J Bone Miner Res</i> , 7(5):523-30, (1992).	
	A25	Ecarot et al., "Phosphate transport by osteoblasts from X-linked hypophosphatemic mice," <i>Am J Physiol</i> , 266:E33-E38, (1994).	
	A26	Econs et al., "Tumour induced osteomalacia-unveiling a new hormone," <i>New Engl J Med</i> , 330(23), 1679-81 (1994).	
	A27	Feng et al., "NF-kappaB specifically activates BMP-2 gene expression in growth plate chondrocytes in vivo and in a chondrocyte cell line in vitro," <i>J Biol Chem</i> , 278:22913-20, (2003).	
	A28	Fisher et al., "Flexible structures of SIBLING proteins, bone sialoprotein, and osteopontin," <i>Biochemical and Biophysical Research Communications</i> , 280:460-65, (2001).	
	A29	Frances et al., "A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets," <i>Nat Genet</i> , 11:130-6, (1995).	
	A30	Frances et al., "Genomic organization of the human PEX gene mutated in X-linked dominant hypophosphatemic rickets," <i>Gen Res</i> , 7(6):573-85, (1997).	
	A31	Francis et al., "Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo," <i>Science</i> , 165:1264-6, (1969).	
	A32	Garrett et al., "Selective inhibitors of the osteoblast proteasome stimulate bone formation <i>in vivo</i> and <i>in vitro</i> ," <i>J Clin Invest</i> , 111(11):1771-82, (2003).	
	A33	Gowen, et al., "Targeted disruption of the osteoblast/osteocyte factor 45 gene (OF45) results in increased bone formation and bone mass," <i>J Biol Chem</i> , 278:1998-2007, (2003).	
	A34	Grant No. 1RO-3 DE015900-01 – Awarded by the National Institute of Dental and Craniofacial Research.	
	A35	Grant No. RO-1 AR51598-01 – Awarded by the National Institute of Arthritis and Musculoskeletal Skin Diseases.	
	A36	Green et al., "Evidence for a PTH-independent humoral mechanism in post-transplant hypophosphatemia and phosphaturia," <i>Kidney Int</i> , 60:1182-96, (2001).	
	A37	Guo et al., "Analysis of recombinant Phex: an endopeptidase in search of a substrate," <i>Am J Physiol Endocrinol Metab</i> , 281:E837-47, (2001).	
	A38	Guo et al., "Inhibition of MEPE cleavage by PHEX," <i>Biochem Biophys Res Comm</i> , 297(1):38-45, 2002.	
	A39	Halstead et al., "Comparison of 22-oxacalcitriol and 1,25(OH)2D3 on bone metabolism in young X-linked hypophosphatemic male mice," <i>American Journal of Physiology</i> , 270:E141-47, (1996).	

Examiner Signature:	Date Considered:
<b>EXAMINER:</b> Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

<b>INFORMATION DISCLOSURE STATEMENT LIST</b>  (Use as many sheets as necessary)		Complete if Known	
		Application No.	10/567,938
		Filing Date	February 9, 2006
		First Named Inventor	Rowe, Peter S.N.
		Group Art Unit	Unassigned
Examiner Name	Unassigned		
	A40	Harris et al., "Effects of transforming growth factor beta on bone nodule formation and expression of bone morphogenetic protein 2, osteocalcin, osteopontin, alkaline phosphatase, and type I collagen mRNA in long-term cultures of fetal rat calvarial osteoblasts," <i>J Bone Miner Res</i> , 9:855-63, (1994).	
	A41	Harris et al., "Expression of bone morphogenetic protein messenger RNA in prolonged cultures of fetal rat calvarial cells," <i>J Bone Miner Res</i> , 9:389-94, (1994).	
	A42	Harris et al., "Recombinant bone morphogenetic protein 2 accelerates bone cell differentiation and stimulates BMP 2 mRNA expression and BMP2 promoter activity in primary fetal rat calvarial osteoblast cultures," <i>Mol Cell Diff</i> , 3:137-155, (1995).	
	A43	He et al., "Nucleation of apatite crystals in vitro by self-assembled dentin matrix protein 1," <i>Nat Mater</i> , 2:552-8, (2003).	
	A44	Hoyer et al., "Phosphorylated osteopontin peptides suppress crystallization by inhibiting the growth of calcium oxalate crystals," <i>Kidney Int</i> , 60:77-82, (2001).	
	A45	International Preliminary Report on Patentability, date of mailing March 30, 2006, Application No. PCT/US2004/030530.	
	A46	International Search Report, date of mailing; 3/7/2006, Application No. PCT/US2004/030530.	
	A47	Invitation To Pay Additional Fees, date of mailing 03/24/2005, Application No. PCT/US2004/030530.	
	A48	Jo et al., "Cathepsin D (Cat D) and bone defect in hypophosphatemic (Hyp) mice," <i>J Am Soc Nephrol</i> 11, Abstract A2141, pp 408A, (2000).	
	A49	Jo et al., "Increased apoptosis in Hyp mouse bone. Potential role of cathepsin D," <i>J Am Soc Nephrol</i> 12, Abstract A3881, pp 743A, (2001).	
	A50	Jonsson et al., "Extracts from tumors causing oncogenic osteomalacia inhibit phosphate uptake in opossum kidney cells," <i>J Endocrinol</i> , 169:613-20, (2001).	
	A51	Lajeunesse et al., "Direct demonstration of a humorally-mediated inhibition of renal phosphate transport in the Hyp mouse," <i>Kidney Int</i> , 50:1531-38, (1996).	
	A52	Lawson-Matthew et al., "Contrasting effects of intravenous and oral etidronate on vitamin D metabolism in man," <i>Clin Sci (Lond)</i> , 74:101-6, (1988).	
	A53	Lee et al., "Proteolytic processing of big endothelin-3 by the Kell blood group protein," <i>Blood</i> 94, 1440-50, (1999).	
	A54	Lemire et al., "Secretion of a type II integral membrane protein induced by mutation of the transmembrane segment," <i>Biochem J</i> , 322(Pt 1):335-42, (1997).	
	A55	Liu et al., "Regulation of FGF23 expression but not degradation by phex," <i>J Biol Chem</i> , 277:3686-97, (2002).	
	A56	Liu et al., "Overexpression of Phex in osteoblasts fails to rescue the Hyp mouse phenotype," <i>J Biol Chem</i> , 277:3686-97, (2002).	
	A57	Loghman-Adham and Dousa, "Dual action of phosphonoformic acid on Na(+)-phosphate cotransport in opossum kidney cells," <i>Am J Physiol</i> , 263:F301-10, (1992).	
	A58	Long et al., "A peptide that inhibits hydroxyapatite growth is in an extended conformation on the crystal surface," <i>Proc Natl Acad Sci, USA</i> , 95:12083-7, (1998).	
	A59	MacDougall et al., "MEPE/OF45, a new dentin/bone matrix protein and candidate gene for dentin diseases mapping to chromosome 4q21," <i>Connect Tissue Res</i> , 43:320-30, (2002).	
	A60	McCloskey et al., "Comparative effects of intravenous diphosphonates on calcium and skeletal metabolism in man," <i>Bone</i> , 8(Suppl 1):S35-41, (1987).	
	A61	McCloskey et al., "Diphosphonates and phosphate homeostasis in man," <i>Clin Sci (Lond)</i> , 74:607-12, (1988).	

Examiner Signature:	Date Considered:
<b>EXAMINER:</b> Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

<b>INFORMATION DISCLOSURE STATEMENT LIST</b>  (Use as many sheets as necessary)		Complete if Known	
		Application No.	10/567,938
		Filing Date	February 9, 2006
		First Named Inventor	Rowe, Peter S.N.
		Group Art Unit	Unassigned
		Examiner Name	Unassigned

A62	Meyer et al., "Parabiosis suggests a humoral factor is involved in X-linked hypophosphataemia in mice," <i>J Bone Miner Res</i> , 4(4):493-500, (1989).
A63	Meyer et al., "The renal phosphate transport defect in normal mice parabiosed to X-linked hypophosphataemic mice persists after Parathyroidectomy," <i>J Bone Miner Res</i> , 4(4):523-32, (1989).
A64	Miao et al., "Osteomalacia in hyp mice is associated with abnormal phex expression and with altered bone matrix protein expression and deposition," <i>Endocrinology</i> , 142:926-39, (2001).
A65	Miyauchi et al., "Hemangiopericytoma induced osteomalacia: Tumour transplantation in nude mice causes hypophosphataemia and tumour extracts inhibit renal 25-hydroxyvitamin D a1-hydroxylase activity," <i>J.Clin.Endocrinol.Metab</i> , 67(1):46-53, (1988).
A66	Morgan et al., "A conserved clathrin assembly motif essential for synaptic vesicle endocytosis," <i>J Neurosci</i> , 20(23):8667-76, (2000).
A67	Morgan et al., "Eps15 homology domain-NPF motif interactions regulate clathrin coat assembly during synaptic vesicle recycling," <i>J Biol Chem</i> , 278(35):33583-92, (2003).
A68	Morgan et al., "Uncoating of clathrin-coated vesicles in presynaptic terminals: Roles for Hsc70 and auxilin," <i>Neuron</i> , 32(2):289-300, (2001).
A69	Mundy et al., "Stimulation of bone formation in vitro and in rodents by statins," <i>Science</i> , 286:1946-9, (1999).
A70	Nesbitt et al., "Coordinated maturational regulation of PHEX and renal phosphate transport inhibitory activity: evidence for the pathophysiological role of PHEX in X-linked hypophosphatemia," <i>J Bone Miner Res</i> , 14:2027-35, (1999).
A71	Nesbitt et al., "Crosstransplantation of kidneys in normal and Hyp mice: Evidence that the Hyp mouse phenotype is unrelated to an intrinsic renal defect," <i>J Clin Invest</i> , 89:1453-59, (1992).
A72	Nesbitt et al., "Phosphate transport in immortalized cell cultures from the renal proximal tubule of normal and Hyp mice: evidence that the HYP gene locus product is an extrarenal factor," <i>J Bone Miner Res</i> , 10:1327-33, (1995).
A73	Oursler et al., "Glucocorticoid-induced activation of latent transforming growth factor-beta by normal human osteoblast-like cells," <i>Endocrinology</i> , 133:2187-96, (1993).
A74	Petersen et al., "Identification of osteoblast/osteocyte factor 45 (OF45) a bone specific cDNA encoding an RGD containing protein that is highly expressed in osteoblasts and osteocytes," <i>J Biol Chem</i> , (2000).
A75	Qin et al., "Evidence for the proteolytic processing of dentin matrix protein 1: Identification and characterization of processed fragments and cleavage sites," <i>J Biol Chem</i> , 17:17, (2003).
A76	Quarles et al., "FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization," <i>Am J Physiol Endocrinol Metab</i> , 285: E1-9, (2003).
A77	Quarles et al., "Pathophysiology of X-linked hypophosphatemia, tumor-induced osteomalacia, and autosomal dominant hypophosphatemia: a perPHEXing problem," <i>J Clin Endocrinol Metab</i> , 86:494-6, (2001).
A78	Raj et al., "Salivary statherin. Dependence on sequence, charge, hydrogen bonding potency, and helical conformation for adsorption to hydroxyapatite and inhibition of mineralization," <i>J Biol Chem</i> , 267:5968-76, (1992).
A79	Reinhardt et al., "A microassay for 1,25-dihydroxyvitamin D not requiring high performance liquid chromatography: application to clinical studies," <i>J Clin Endocrinol Metab</i> , 58:91-8, (1984).
A80	Rifas et al., "Skeletal casein kinase activity defect in the HYP mouse," <i>Calcif. Tissue Int</i> , 61:256-59, (1997).

Examiner Signature:	Date Considered:
<b>EXAMINER:</b> Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

<b>INFORMATION DISCLOSURE STATEMENT LIST</b>  (Use as many sheets as necessary)		Complete if Known	
		Application No.	10/567,938
		Filing Date	February 9, 2006
		First Named Inventor	Rowe, Peter S.N.
		Group Art Unit	Unassigned
Examiner Name	Unassigned		
A81		Rifas et al., "Altered osteoblast gluconeogenesis in X-linked hypophosphatemic mice is associated with a depressed intracellular pH," <i>Calcif. Tissue Int</i> , 57:60-3, (1995).	
A82		Rowe et al., "Candidate 56 and 58 kDa protein(s) responsible for mediating the renal defects in oncogenic hypophosphatemic osteomalacia," <i>Bone</i> , 18(2):159-69, (1996).	
A83		Rowe et al., "Distribution of mutations in the PEX gene in families with X-linked hypophosphatemic rickets (HYP)," <i>Hum Mol. Genet</i> , 6:539-49, (1997).	
A84		Rowe et al., "MEPE has the properties of an osteoblastic phosphatonin and minihabin: evidence for a novel PHEX-mediated mechanism," <i>Bone</i> , 34:303-19, (2004).	
A85		Rowe et al., "MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia," <i>Genomics</i> , 67:54-68, (2000).	
A86		Rowe et al., "Surface plasma resonance (SPR) confirms that MEPE binds to PHEX via the MEPE-ASARM motif: a model for impaired mineralization in x-linked rickets (HYP)," <i>Bone</i> , 36(1):33-46, (2004).	
A87		Rowe et al., "The gene for X-linked hypophosphatemic rickets maps to a 200-300 kb region in Xp22.1, and is located on a single YAC containing a putative vitamin D response element (VDRE)," <i>Human Genetics</i> , 97:345-52, (1996).	
A88		Rowe et al., "The Wrickkened Pathways of FHF23, MEPE and PHEX," <i>Curr Review Oral Biol &amp; Med</i> , 15(5):264-81, (2004).	
A89		Rowe et al., "Refining the genetic map for the region flanking the X-linked hypophosphatemic rickets locus (Xp22.1-22.2)," <i>Hum Genet</i> , 93:291-4, (1994).	
A90		Rowe Presentation – ASBMR 25 <sup>th</sup> Annual Meeting, Minneapolis, September 18-23, 2003, presented on September 19, 2003. (Abstract).	
A91		Rowe, "Molecular Biology of Hypophosphatemic Rickets and Oncogenic Osteomalacia," <i>Hum Genet</i> , 94(5):457-67, (1994).	
A92		Rowe, "The PEX gene: its role in X-linked rickets, osteomalacia, and bone mineral metabolism," <i>Exp Nephrol.</i> , 5:355-63, (1997).	
A93		Rowe, "The role of the PHEX gene (PEX), in families with X-linked hypophosphatemic rickets," <i>Current Opinion in Nephrology &amp; Hypertension</i> , 7(4):367-76, (1998).	
A94		Rowe, "The molecular background to hypophosphatemic rickets," <i>Arch Dis Child</i> , 83:192-4, (2000).	
A95		Saito et al., "Mineral induction by immobilized phosphoproteins," <i>Bone</i> , 21:305-11, (1997).	
A96		Sanderson and Bachus, "Staining technique to differentiate mineralized and demineralized bone in ground sections," <i>J Histotechnol</i> , 20(2):119-122, (1997).	
A97		Schlesinger and Hay, "Complete covalent structure of statherin, a tyrosine-rich acidic peptide which inhibits calcium phosphate precipitation from human parotid saliva," <i>J Biol Chem</i> , 252:1689-95, (1977).	
A98		Schwartz et al., "Inhibition of calcium phosphate precipitation by human salivary statherin: structure-activity relationships," <i>Calcif Tissue Int</i> , 50:511-7, (1992).	
A99		Shih et al., "Effects of PHEX antisense in human osteoblast cells," <i>J Am Soc Nephrol</i> , 13:394-9, (2002).	
A100		Shimada et al., "Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia," <i>Proc Natl Acad Sci USA</i> , 98:6500-5, (2001).	
A101		Shimada et al., "Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia <i>in vivo</i> ," <i>Endocrinology</i> , 143:3179-82, (2002).	

Examiner Signature:	Date Considered:
<b>EXAMINER:</b> Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

<b>INFORMATION DISCLOSURE STATEMENT LIST</b>  (Use as many sheets as necessary)		Complete if Known	
		Application No.	10/567,938
		Filing Date	February 9, 2006
		First Named Inventor	Rowe, Peter S.N.
		Group Art Unit	Unassigned
Examiner Name	Unassigned		
A102		Soiffer et al., "Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma," <i>J Clin Oncol</i> , 1(17):3343-50, (2003).	
A103		Stoll et al., "Effect of diphosphonate treatment on phosphate transport by renal brush border vesicles," <i>Am J Physiol</i> , 239:F13-6, (1980).	
A104		Strom et al., <i>Hum Mol Genet</i> , 6(2):165-71, (1997).	
A105		Trechsel et al., "Relation between bone mineralization, Ca absorption, and plasma Ca in phosphonate-treated rats," <i>Am J Physiol</i> , 232(3):E298-305, (1977).	
A106		Turner et al., "The neprilysin (NEP) family of zinc metalloendopeptidases: genomics and function." <i>Bioassays</i> , 23:261-9, (2001).	
A107		Unterbrink et al., "Characterization of MEPE genomic organization and expression during odontogenesis," <i>The IADR/AADR/CADR 80th General Session</i> , San Diego, California, Seq: 304, Abstract 4117, (2002).	
A108		VanScoy et al., "Mechanism of phosphaturia elicited by administration of phosphonoformate in vivo," <i>Am J Physiol</i> , 255:F984-94, (1988).	
A109		Walton et al., "Changes in the renal and extrarenal handling of phosphate induced by disodium etidronate (EHDP) in man," <i>Clin Sci Mol Med</i> , 49:45-56, (1975).	
A110		Wesson et al., "Osteopontin is a critical inhibitor of calcium oxalate crystal formation and retention in renal tubules," <i>J Am Soc Nephrol</i> , 14:139-47, (2003).	
A111		White et al., "Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23," <i>Nature Genetics</i> , 26:345-8, (2000).	
A112		White et al., "The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting," <i>Journal of Clinical Endocrinology and Metabolism</i> , 86:497-500, (2001).	
A113		Wilkins et al., "Oncogenic osteomalacia: evidence for a humoral phosphaturic factor," <i>J Clin Endocrinol Metab</i> , 80:1628-34, (1995).	
A114		Xiao et al., "Intrinsic mineralization defect in Hyp mouse osteoblasts," <i>Am J Physiol</i> , 275:E700-8, (1998).	
A115		Yamamoto et al., "Abnormal response of osteoblasts from Hyp mice to 1,25-dihydroxyvitamin D3," <i>Bone</i> , 13:209-15, (1992).	
A116		Yamashita et al., "Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain," <i>Biochem Biophys Res Commun</i> , 277:494-8, (2000).	
A117		Zhao et al., "Bone morphogenic protein receptor signaling is necessary for normal murine postnatal bone formation," <i>J Cell Biol</i> , 157:1049-60, (2002).	
A118		Zhao et al., "E3 ubiquitin ligase smurf1 mediates core-binding factor {alpha}1/runx2 degradation and plays a specific role in osteoblast differentiation," <i>J Biol Chem</i> , 278:27939-44, (2003).	
A119		Zhou et al., "CBFA1 mutation analysis and functional correlation with phenotypic variability in cleidocranial dysplasia," <i>Hum. Mol Genet</i> , 8:2311-16, (1999).	

Examiner Signature:	Date Considered:
<b>EXAMINER:</b> Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	